Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier.

ABSTRACT: Simnotrelvir is an oral small-molecule antiviral agent targeting the 3C-like protease (3CL^pro) of SARS-CoV-2, proven effective against the Delta variant with favorable pharmacokinetics and safety in preclinical study. In this study, we further evaluated the antiviral efficacy of simnotrelvir against a range of emerging Omicron variants, including BA.1, BA.4, BA.5, CH.1.1, XBB.1.5, XBB.1.16, EG.5, and JN.1. In vitro assays with Vero E6 cells confirmed that simnotrelvir exhibited robust antiviral activity across these variants, comparable to the Food and Drug Administration (FDA)-approved drug nirmatrelvir. Additionally, simnotrelvir demonstrated effective inhibition against several nirmatrelvir-resistant SARS-CoV-2 3CL^pro mutants, including A260V, Y54A, (T21I +

SUBMITTER: Zhao L 

PROVIDER: S-EPMC11963564 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature